The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically benefitted from therapy with PARP inhibitor (PARPi) or platinum compounds, but acquired resistance limits clinical impact. In this study, we investigated the impact of mutations on BRCA1 isoform expression and th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Principais autores: Wang, Yifan, Bernhardy, Andrea J., Cruz, Cristina, Krais, John J., Nacson, Joseph, Nicolas, Emmanuelle, Peri, Suraj, van der Gulden, Hanneke, van der Heijden, Ingrid, O'Brien, Shane W., Zhang, Yong, Harrell, Maribel I., Johnson, Shawn F., Candido Dos Reis, Francisco J., Pharoah, Paul D. P., Karlan, Beth, Gourley, Charlie, Lambrechts, Diether, Chenevix-Trench, Georgia, Olsson, Håkan, Benitez, Javier J., Greene, Mark H., Gore, Martin, Nussbaum, Robert, Sadetzki, Siegal, Gayther, Simon A., Kjaer, Susanne K., D'Andrea, Alan D., Shapiro, Geoffrey I., Wiest, David L., Connolly, Denise C., Daly, Mary B., Swisher, Elizabeth M., Bouwman, Peter, Jonkers, Jos, Balmaña, Judith, Serra, Violeta, Johnson, Neil
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4874568/
https://ncbi.nlm.nih.gov/pubmed/27197267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-0186
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados